Lung Cancer Clinical Trials in Philadelphia

Showing 301-320 of 592 trials

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

NCT04903873

Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).

Solid TumorRenal Cell Cancer MetastaticNon-Small Cell Lung Cancer+2 more

Eutilex110 participantsStarted May 2021

Philadelphia, Pennsylvania, United States • Dallas, Texas, United States • Ilsan, South Korea +3 more locations

TERMINATEDPhase 1< 1 mile

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Non-Small Cell Lung CancerOvarian CancerFallopian Tube Cancer+3 more

Kite, A Gilead Company16 participantsStarted Oct 2019

Phoenix, Arizona, United States • Los Angeles, California, United States • Tampa, Florida, United States +7 more locations

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Lung Cancer Trials in Other Cities

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Risk Communication in African American Smokers

A Study of PRT2527 in Participants With Advanced Solid Tumors

Prospective Clinicogenomic Program

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung EpiCheck Biomarkers Development Study

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in Philadelphia